Related Experiment Videos
Pityriasis rubra pilaris in childhood: a long-term study of 29 cases
Insights
Pityriasis rubra pilaris (PRP) in children often presents as an acute, self-resolving condition. This pediatric dermatosis typically resolves spontaneously within months, suggesting conservative management is often sufficient.
Area of Science:
- Dermatology
- Pediatrics
Background:
- Pityriasis rubra pilaris (PRP) is a rare dermatosis of unknown etiology.
- Pediatric cases represent a small fraction (0.2%) of hospitalized pediatric patients.
Purpose of the Study:
- To analyze the clinical characteristics and prognosis of childhood Pityriasis rubra pilaris.
- To evaluate the optimal management strategies for juvenile PRP.
Main Methods:
- Retrospective review of 31 new cases of pediatric PRP observed over 20 years.
- Follow-up data collected for 29 children with the condition.
Main Results:
- The acute, self-resolving form of PRP is more common in children than adults.
- No hereditary cases were identified, and disease severity did not correlate with prognosis.
- Juvenile PRP typically follows a rapid course with spontaneous resolution within months.
Conclusions:
- Conservative management is generally recommended for juvenile Pityriasis rubra pilaris due to its favorable prognosis.
- Synthetic retinoids are reserved for persistent and disabling cases of pediatric PRP.
Abstract:
Pityriasis rubra pilaris (PRP) is a dermatosis of unknown origin with a limited frequency in childhood (0.2% of our hospitalized pediatric patients). During the last 20 years we have observed 31 new cases; follow-up has been conducted in 29 children. The acute self-resolving form seems to be the most frequent in children, compared to adults. No cases of hereditary PRP have been observed, and no relationship between the severity of PRP and its prognosis has been reported. Since juvenile PRP has a relatively rapid course and a spontaneous resolution (a few months), it seems unnecessary to use potentially harmful drugs. Synthetic retinoids may be employed in patients whose disease is both persistent and disabling.